The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Blood

Volumn 100, Issue 5, 2002, Pages 1628-1633

  O'Dwyer, Michael E ^a,b,c   Mauro, Michael J ^a,b,c   Kurilik, Gwen ^a,b,c   Mori, Motomi ^a,b,c   Balleisen, Suzanne ^a,b,c   Olson, Susan ^a,b,c   Magenis, Ellen ^a,b,c   Capdeville, Renaud ^a,b,c   Druker, Brian J ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036720397     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0777     Document Type: Article

References (24)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
3. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
4. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
5. Recent advancements in the treatment of chronic myelogenous leukemia
6. Characteristics of accelerated disease in chronic myelogenous leukemia
7. Cytogenetics of chronic myelogenous leukemia
8. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia
9. Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival
10. Chronic myeloid leukemia in accelerated phase: Treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients
11. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases
12. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
13. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
14. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
15. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia
16. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine
17. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia
18. Staging and prognosis in chronic myelogenous leukemia
19. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
20. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase
21. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy
22. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
23. Myeloid growth factors for neutropenia during Imatinib mesylate (STI571) therapy for CML: Preliminary evidence of safety and efficacy